Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression

Molecular and Cellular Biology

Volumn 17, Issue 12, 1997, Pages 7195-7207

  Qi, Jian Shen ^a   Desai Yajnik, Vandana ^a   Yuan, Yaping ^a   Samuels, Herbert H ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; PROTEIN P53; THYROID HORMONE RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; GENE ACTIVATION; GENE REPRESSION; HELA CELL; HUMAN; HUMAN CELL; HYPOPHYSIS CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALIA; GALLUS GALLUS;

EID: 0030667318     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.12.7195     Document Type: Article

References (104)

1. Au-Fliegner, M., E. Helmer, J. Casanova, B. M. Raaka, and H. H. Samuels. 1993. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation. Mol. Cell. Biol. 13:5725-5737.
2. Baker, S. J., S. Markowitz, E. R. Fearon, J. K. U. Willson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915.
3. Baniahmad, A., C. A. Kohne, and R. Renkawitz. 1992. A transferable silencing domain is present in the thyroid hormone receptor, in the v-erbA oncogene product and in the retinoic acid receptor. EMBO J. 11:1015-1023.
4. Baniahmad, A., X. Leng, T. P. Burris, S. Y. Tsai, M.-J. Tsai, and B. W. O'Malley. 1995. The τ4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. Mol. Cell. Biol. 15:76-86.
5. Barak, Y. T., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461-468.
6. Bischoff, J. R., P. N. Friedman, D. R. Marshak, C. Prives, and D. Beach. 1990. Human p53 is phosphorylated by p60-cdc and cyclinB-cdc2. Proc. Natl. Acad. Sci. USA 87:4766-4770.
7. Brent, G. A., M. K. Dunn, J. W. Harney, T. Gulick, P. R. Larsen, and D. D. Moore. 1989. Thyroid hormone aporeceptor represses T3-inducible promoters and blocks activity of the retinoic acid receptor. New Biol. 1:329-336.
8. Casanova, J., E. Helmer, S. Selmi-Ruby, J.-S. Qi, M. Au-Fliegner, V. Desai-Yajnik, N. Koudinova, F. Yarm, B. M. Raaka, and H. H. Samuels. 1994. Functional evidence for ligand-dependent dissociation of thyroid hormone and retinoic acid receptors from an inhibitory cellular factor. Mol. Cell. Biol. 14:5756-5765.
9. Chatterjee, V. K. K., J.-K. Lee, A. Rentoumis, and J. L. Jameson. 1989. Negative regulation of the thyroid stimulating hormone alpha gene by thyroid hormone: receptor interaction adjacent to the TATA box. Proc. Natl. Acad. Sci. USA 86:9114-9118.
10. Chen, J. D., and R. M. Evans. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457.
11. Chiang, C. M., and R. G. Roeder. 1995. Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators. Science 267:531-536.
12. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
13. Damm, K., C. C. Thompson, and R. M. Evans. 1989. Protein encoded by v-erbA functions as a thyroid hormone receptor antagonist. Nature 339: 593-597.
14. Dayton, A. I., J. G. Sodroski, C. A, Rosen, W. C. Goh, and W. A. Haseltine. 1986. The trans-activator gene of the human T-cell lymphotrophic virus type III is required for replication. Cell 44:941-947.
15. Desai-Yajnik, V., E. Hadzic, P. Modlinger, S. Malhotra, and H. H. Samuels. 1995. Interactions of thyroid hormone receptor with the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and the HIV-1 trans-activator, tat. J. Virol. 69:5103-5112.
16. Desai-Yajnik, V., and H. H. Samuels. 1993. The NF-κB and Sp1 DNA motifs of the human immunodeficiency virus type 1 long terminal repeat function as novel thyroid hormone response elements. Mol. Cell. Biol. 13:5057-5069.
17. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489.
18. Dittmer, D., S. Pati, G. Zambetti, S. Chu, A. K. Teresky, M. Moore, C. Finlay, and A. J. Levine. 1993. Gain of function mutations in p53. Nat. Genet. 4:42-46.
19. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
20. Evans, R. M. 1988. The steroid and thyroid hormone receptor superfamily. Science 240:889-895.
21. Fields, S., and S. K. Jang. 1990. The p53 proto-oncogene can act as a suppressor of transformation. Science 249:1046-1049.
22. Fisher, A. G., M. B. Feinberg, S. F. Josephs, M. E. Harper, L. M. Marselle, G. Reyes, M. A. Gonda, A. Aldovini, C. Debouk, R. C. Gallo, and F. Wang-Stall. 1986. The transactivator gene of HTLV-III is essential for virus replication. Nature 320:367-371.
23. Flug, F., R. P. Copp, J. Casanova, Z. D. Horowitz, L. Janocko, M. Plotnick, and H. Samuels. 1987. cis-acting elements of the rat growth hormone gene which mediate basal and regulated expression by thyroid hormone. J. Biol. Chem. 262:6373-6382.
24. Forman, B. M., J. Casanova, B. M. Raaka, J. Ghysdael, and H. H. Samuels. 1992. Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. Mol. Endocrinol. 6:429-442.
25. Forman, B. M., and H. H. Samuels. 1990. Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. Mol. Endocrinol. 4:1293-1301.
26. Forman, B. M., and H. H. Samuels. 1991. pEXPRESS: a family of expression vectors containing a single transcription unit active in prokaryotes, eukaryotes and in vitro. Gene 105:9-15.
27. Forman, B. M., K. Umesono, J. Chen, and R. M. Evans. 1995. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell 81:541-550.
28. Forman, B. M., C.-R. Yang, M. Au, J. Casanova, J. Ghysdael, and H. H. Samuels. 1989. A domain containing leucine zipper like motifs mediates novel in vivo interactions between the thyroid hormone and retinoic acid receptors. Mol. Endocrinol. 3:1610-1626.
29. Forman, B. M., C.-R. Yang, F. Stanley, J. Casanova, and H. H. Samuels. 1988. c-erbA protooncogenes mediate thyroid hormone-dependent and independent regulation of the rat growth hormone and prolactin genes. Mol. Endocrinol. 2:902-911.
30. Freedman, L. P. 1992. Anatomy of the steroid receptor zinc finger region. Endocrinol. Rev. 13:129-145.
31. Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88:9979-9983.
32. Hadzic, E., V. Desai-Yajnik, E. Helmer, S. Guo, J. Casanova, B. M. Raaka, and H. H. Samuels. 1995. A 10-amino-acid sequence in the N-terminal A/B domain of thyroid hormone receptor α is essential for transcriptional activation and interaction with the general transcription factor TFIIB. Mol. Cell. Biol. 15:4507-4517.
33. Haines, D. S., J. E. Landers, L. J. Engle, and D. L. George. 1994. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol. 14:1171-1178.
34. Harvey, M., H. Vogel, D. Morris, A. Bradley, A. Bernstein, and L. A. Donehower. 1995. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:305-311.
35. Haupt, Y., Y. Barak, and M. Oren. 1996. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15:1596-1606.
36. Helmer, E. B., B. M. Raaka, and H. H. Samuels. 1996. Hormone-dependent and -independent transcriptional activation by thyroid hormone receptors are mediated by different mechanisms. Endocrinology 137:390-399.
37. Herrmann, C. H., and A. P. Rice. 1993. Specific interactions of the human immunodeficiency virus tat proteins with a cellular protein kinase. Virology 197:601-608.
38. Hodin, R., M. A. Lazar, B. I. Wintman, D. S. Darling, R. J. Koenig, P. R. Larsen, D. D. Moore, and W. W. Chin. 1989. Identification of a thyroid hormone receptor that is pituitary-specific. Science 244:76-79.
39. Horlein, A. J., A. M. Naar, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamil, M. Soderstrom, C. K. Glass, and M. G. Rosenfeld. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404.
40. Horowitz, Z. D., C.-R. Yang, B. M. Forman, J. Casanova, and H. H. Samuels. 1989. Characterization of the domain structure of chick c-erbA by deletion mutation: in vitro translation and cell transfection studies. Mol. Endocrinol. 3:148-156.
41. Juven, T., Y. Barak, A. Zauberman, D. L. George, and M. Oren. 1993. Wild-type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416.
42. Kastan, M. B., Q. Zhan, W. S. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, and A. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia Telangiectasia. Cell 71: 587-597.
43. Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-bindins protein. Science 252:1708-1711.
44. Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
45. Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
46. Landers, J. E., D. S. Haines, J. F. Strauss III, and D. L. George. 1994. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9:2745-2750.
47. Lane, D. P., and L. V. Crawford. 1979. T antigen is bound to host protein in SV40 transformed cells. Nature 278:261-263.
48. Lazar, M. A. 1993. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocrinol. Rev. 14:184-193.
49. Lee, J. W., F. Ryan, J. C. Swaffield, S. A. Johnston, and D. D. Moore. 1995. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 374:91-94.
50. Lezoualch, F., A. H. S. Hassan, P. Giraud, J.-P. Loeffler, S. L. Lee, and B. A. Demeneix. 1992. Assignment of the β-thyroid hormone receptor to 3,5,3′-triiodothyronine-dependent inhibition of transcription from the thyrotropin-releasing hormone promoter in chick hypothalamic neurons. Mol. Endocrinol. 6:1797-1804.
51. Lillie, J. W., and M. R. Green. 1989. Transcription activation by the adenovirus E1a protein. Nature 338:39-44.
52. Lin, J., J. Chen, B. Elenbaas, and A. J. Levine. 1994. Several Hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1235-1246.
53. Linzer, D. I., and A. J. Levine. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17:43-52.
54. Liu, X., C. W. Miller, P. H. Koeffler, and A. J. Berk. 1993. The p53 activation domain binds the TATA box-binding polypeptide in holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13: 3291-3300.
55. Mack, D. H., J. Vartikar, J. M. Pipas, and L. Laimins. 1993. Specific repression of TATA-mediated but not initiator mediated transcription by wild-type p53. Nature 363:281-283.
56. Maheswaran, S., C. Englert, P. Bennett, G. Heinrich, and D. A. Haber. 1995. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 9:2143-2156.
57. Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, and R. M. Evans. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-839.
58. Masuda, H., C. Miller, H. P. Koeffler, H. Battifora, and M. J. Cline. 1987. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA 84:7716-7719.
59. Morris, G. F., and M. B. Mathews. 1991. The adenovirus E1A transforming protein activates the proliferating cell nuclear antigen promoter via an activating transcription factor site. J. Virol. 65:6397-6406.
60. Munoz, A., M. Zenke, U. Gehring, J. Sap, H. Beug, and B. Vennstrom. 1988. Characterization of the hormone-binding domain of the chicken c-erbA/ thyroid hormone receptor protein. EMBO J. 7:155-159.
61. Onate, S. A., S. Y. Tsai, M.-J. -. Tsai, and B. W. O'Malley. 1995. Sequence and characterization of a coactivator of the steroid hormone receptor superfamily. Science 270:1354-1357.
62. Oren, M., W. Maltzman, and A. J. Levine. 1981. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol. 1:101-110.
63. O'Shea-Greenfield, A., and S. T. Smale. 1992. Roles of TATA and initiator elements in determining the start site location and direction of RNA polymerase II transcription. J. Biol. Chem. 267:1391-1402.
64. Pinhasi-Kimhi, O., D. Michalovitz, D. Ben-Zeev, and M. Oren. 1986. Specific interaction between the p53 cellular tumor antigen and the major heat shock protein. Nature 320:182-185.
65. Powers, C. A., M. Mathur, B. M. Raaka, D. Ron, and H. H. Samuels. TLS is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol. Endocrinol., in press.
66. Qi, J.-S., V. Desai-Yajnik, M. E. Greene, B. M. Raaka, and H. H. Samuels. 1995. The ligand binding domains of the thyroid hormone/retinoid receptor gene subfamily function in vivo to mediate heterodimerization, gene silencing and transactivation. Mol. Cell. Biol. 15:1817-1825.
67. Qi, J.-S., V. Desai-Yajnik, and H. H. Samuels. 1996. Molecular interactions of p53 with thyroid hormone nuclear receptors. J. Invest. Med. 44:234A.
68. Qin, X., T. Chittenden, D. M. Livingston, and J. W G Kaelin. 1992. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 6:953-964.
69. Reich, N. C., M. Oren, and A. J. Levine. 1983. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol. 3:2143-2150.
70. Rhim, H., C. O. Echetebu, C. H. Herrman, and A. P. Rice. 1994. Wild-type and mutant HIV-1 and HIV-2 tat proteins expressed in Escherichia coli as fusions with glutathione S-transferase. J. Acquired Immune Defic. Syndr. 7:1116-1121.
71. Saatcioglu, F., T. Deng, and M. Karin. 1993. A novel cis element mediating ligand-independent activation by c-erbA: implications for hormonal regulation. Cell 75:1095-1105.
72. Sabbatini, P., S. K. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15:1060-1070.
73. Santhanam, U., A. Ray, and P. B. Sehgal. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility product. Proc. Natl. Acad. Sci. USA 88:7605-7609.
74. Sap, J., A. Munoz, K. Damm, Y. Goldberg, J. Ghysdael, A. Leutz, H. Beug, and B. Vennstrom. 1986. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 324:635-640.
75. Schaufele, F., B. L. West, and J. Baxter. 1992. Synergistic activation of the rat growth hormone promoter by Pit-1 and the thyroid hormone receptor. Mol. Endocrinol. 6:656-665.
76. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 61:1129-1136.
77. Selmi, S., and H. H. Samuels. 1991. Thyroid hormone receptor/c-erbA and v-erbA: a single amino acid difference in the C-terminal region influences dominant negative activity and receptor dimer formation. J. Biol. Chem. 266:11589-11593.
78. Selvakumaran, M., H. K. Liu, T. Miyashita, H. G. Wang, S. Krajewski, J. C. Reed, B. Hoffman, and D. Liebermann. 1994. Immediate early up-regulation of bax expression by p53 but not TGFβ1: a paradigm for distinct apoptotic pathways. Oncogene 9:1791-1798.
79. Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12:5581-5592.
80. Shiio, Y., T. Yamamoto, and N. Yamaguchi. 1992. Negative regulation of Rb expression by the p53 gene product. Proc. Natl. Acad. Sci. USA 89: 5206-5210.
81. Smit-McBride, Z., and M. L. Privalsky. 1994. DNA sequence specificity of the v-Erb A oncoprotein/thyroid hormone receptor: role of the P-box and its interaction with more N-terminal determinants of DNA recognition. Mol. Endocrinol. 8:819-828.
82. Smith, D. B., and K. S. Johnson. 1988. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67:31-40.
83. Soussi, T., C. C. deFromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952.
84. Sturzbecher, H. W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J. R. Jenkins. 1992. A C-terminal α-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7:1513-1523.
85. Subler, M. A., D. W. Martin, and S. Deb. 1994. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions. Oncogene 9:1351-1359.
86. Szekely. L., G. Selivanova, K. Magnusson, P. G. Klein, and K. G. Wilman. 1993. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA 90:5455-5459.
87. Tanaka, M., R. Gupta, and B. J. Mayer. 1995. Differential inhibition of signaling pathways by dominant-negative SH2/SH3 adapter proteins. Mol. Cell. Biol. 15:6829-6837.
88. Thomas, M., G. Matlashewski, D. Pim, and L. Banks. 1996. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 13:265-273.
89. Tomic, M., C.-K. Jiang, H. S. Epstein, I. M. Freedberg, H. H. Samuels, and M. Blumenberg. 1990. Nuclear receptors for retinoic acid and thyroid hormone regulate transcription of keratin genes. Cell Reg. 1:965-973.
90. Tomic-Canic, M., D. Day, H. H. Samuels, I. M. Freedberg, and M. Blumenberg. 1996. Novel regulation of keratin gene expression by thyroid hormone and retinoid receptors. J. Biol. Chem. 271:1416-1423.
91. Umesono, K., V. Giguere, C. K. Glass, M. G. Rosenfeld, and R. M. Evans. 1988. Retinoic acid and thyroid hormone induce gene expression through a common responsive element. Nature 336:262-265.
92. Umesono, K., K. K. Murakami, C. C. Thompson, and R. M. Evans. 1991. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D receptors. Cell 65:1255-1266.
93. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev. 7:2575-2586.
94. Ways, D. K., W. Qin, P. Cook, P. J. Parker, J. B. Menke, E. Hao, A. M. Smith, C. Jones, J. M. Hershman, M. E. Geffner, F. Su, H. H. Samuels, and S. J. Usala. 1993. Dominant and non-dominant negative c-erbAβ1 receptors associated with thyroid hormone resistance syndromes augment TPA-induction of the collagenase promoter and exhibit defective T3-mediated repression. Mol. Endocrinol. 7:1112-1120.
95. Weinberger, C., C. C. Thompson, E. S. Ong, R. Lebo, D. J. Gruol, and R. M. Evans. 1986. The c-erb-A gene encodes a thyroid hormone receptor. Nature 324:641-646.
96. Weintraub, H., S. Hauschka, and S. J. Tapscott. 1991. The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA 88:4570-4571.
97. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
98. Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1125-1132.
99. Yamamoto, M., M. Yoshida, K. Ono, T. Fujita, N. Ohtani-Fujita, T. Sakai, and T. Nikaido. 1994. Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression. Exp. Cell Res. 210:94-101.
100. Yap, N., C.-L. Yu, and S.-Y. Cheng. 1996. Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc. Natl. Acad. Sci. USA 93:4273-4277.
101. Yew, P. R., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 347:82-85.
102. Yonish-Ruuach, E., D. Grunwald, S. Wilder, A. Kimchi, E. May, J. J. Lawrence, P. May, and M. Oren. 1993. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol. 13:1415-1423.
103. Zambetti, G. P., J. Bargonetti, K. Walker, C. Prives, and A. J. Levine. 1992. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6:1143-1152.
104. Zenke, M., A. Munoz, J. Sap, B. Vennstrom, and H. Beug. 1990. v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA. Cell 61:1035-1049.